Jason Duncan - 09 Nov 2026 Form 3 Insider Report for enGene Therapeutics Inc. (ENGN)

Reporting relationship: Chief Legal & Admin Officer
Issuer ticker: ENGN
Reported as of: 09 Nov 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 13 Nov 2026, 16:52:26 UTC
Prior SEC filing: 21 Aug 2026
Next SEC filing: 13 Nov 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Shortsleeve as attorney-in fact for Jason Duncan

Filing notes and source

Key filing fact

Jason Duncan filed Form 3 for enGene Therapeutics Inc. (ENGN) on 13 Nov 2026.

Key facts

This page summarizes Jason Duncan's Form 3 filing for enGene Therapeutics Inc. (ENGN).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Nov 2026, 16:52.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

CIK 0001741553 Primary reporting owner

Shares, units, or other non-derivative securities reported in this filing.

ENGN holding

No transaction description listed

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

SEC remarks

Exhibit 24 - Power of Attorney